Real-world evidence (RWE) trials mainly involve observational data outside the traditional involvement of randomised ...

The Norse Eight trial was part of the data requested by the FDA after the agency rejected the BLA for the company’s Lytenava ...

The announcement means the company will be pulling the plug on the CardinALS trial after its ALS drug failed to halt disease ...

Lexicon Pharmaceuticals has completed the enrolment of subjects for the multicentre Phase IIb PROGRESS trial of LX9211 to ...

Amgen reported 20% weight loss in its MariTide Phase II study results, but a 10% drop in share price suggests investors had ...

The Phase III trial of AXS-12 showed results over placebo as the company looks towards a new drug application for its ...

The company’s oral, microbiome-changing therapy was well tolerated in patients with amyotrophic lateral sclerosis.

AstraZeneca has reported positive results from a Phase III trial that evaluated Truqap combined with abiraterone and ADT for ...

MSD has reported that the Phase III ZENITH trial of WINREVAIR for pulmonary arterial hypertension met its primary endpoint.

AL002 is a monoclonal antibody that Alector was developing to slow down Alzheimer’s progression. Image credit: Black Salmon / Shutterstock. Alector’s internal pipeline suffered a blow as the Phase II ...

Following the ReThink study failure, Cassava Sciences is discontinuing the Phase III ReFocus trial and open-label study.

Cybersecurity is another critical issue, as health data is particularly vulnerable to breaches, which can lead to identity ...